Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor

Cancer Research

Volumn 68, Issue 17, 2008, Pages 7083-7089

  Witters, Lois ^a   Scherle, Peggy ^b   Friedman, Steven ^b   Fridman, Jordan ^b   Caulder, Eian ^b   Newton, Robert ^b   Lipton, Allan ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b Experimental Station   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; AMPHIREGULIN; DISINTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GW 2974; INCB 3619; INCB 7839; LAPATINIB; METALLOPROTEINASE INHIBITOR; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; INCB3619; METALLOPROTEINASE; PIPERIDINE DERIVATIVE; PROTEINASE INHIBITOR; SPIRO COMPOUND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; ANIMAL; BREAST TUMOR; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; DISINTEGRINS; FEMALE; HUMANS; METALLOPROTEASES; MICE; PIPERIDINES; PROTEASE INHIBITORS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; SPIRO COMPOUNDS;

EID: 52049111595     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0739     Document Type: Article

References (29)

1. Zhou B-BS, Peyton M, He B, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006;10:1-12.
2. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res 2003;284:2-13.
3. Liu PCC, Liu X, Li Y, et al. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther 2006;5:e1-8.
4. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
5. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55.
6. Mosesson Y, Yarden Y. Oncogenic growth factor receptors: implications for signal transduction therapy. Semin Cancer Biol 2004;14:262-70.
7. Barnes D, Sato G. Serum-free cell culture: a unifying approach. Cell 1980;22:649-55.
8. Osborne CK, Arteaga CL. Autocrine and paracrine growth regulation of breast cancer: clinical implications. Breast Cancer Res Treat 1990;15:3-11.
9. Sporn MB, Totaro GJ. Autocrine secretion and malignant transformation of cells. N Engl J Med 1980;303:878-80.
10. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
11. Umekita Y, Ohi Y, Sagara Y, Yoshida H. Co-expression of epidermal growth factor receptor and transforming growth factor -a predicts worse prognosis in breast cancer patients. Int J Cancer 2000;89:484-7.
12. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 1990;50:7077-80.
13. Gorgoulis V, Aninos D, Mikou P, et al. Expression of EGF, TGF- α, and EGFR in squamous cell lung carcinomas. Anticancer Res 1992;12:1183-7.
14. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94.
15. Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk 1/2 and AKT pathways. Oncogene 2002;21:6255-63.
16. Burris H, Hurwitz H, Dees C, et al. EGF10004: a randomized, multicenter phase Ib study of the safety, biologic activity and clinical efficacy of the dual kinase inhibitor GW572016 [abstract 39]. Breast Cancer Res Treat 2003;82:S18.
17. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
18. Liu X, Fridman JS, Wang Q, et al. Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. Cancer Biol Ther 2006;5:e1-9.
19. Lipton A, Ali SM, Leitzel K, et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002;20:1467-72.
20. Gee JM, Knowlden JM. ADAM metallloproteases and EGFR signalling. Breast Cancer Res 2003;5:223-4.
21. Sahin U, Weskamp G, Kelly K, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004;164:769-79.
22. Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in mammalian development. Science 1998;282:1281-4.
23. Borell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J. TACE is required for the activation of the EGFR by TGF-α in tumors. EMBO J 2003;22:1114-24.
24. Chou T-C, Talalay P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 1977;252:6438-42.
25. Chou T-C, Talalay P. Analysis of combined drug effects: A new look at a very old problem. Trends Pharmacol Sci 1983;4:450-4.
26. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immonotherapeutic target. J Neurovirol 1998;4:148-58.
27. Sergina NV, Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445:437-41.
28. Soltoff SP, Carraway KL III, Prigent SA, Gullick WG, Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994;14:3550-8.
29. Kim HH, Sierke SL, Koland JG. Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. J Biol Chem 1994;269:24747-55.